Pfizer has encountered many setbacks in its quest to launch a medicine that could rival Wegovy and Zepbound. One of its ...

The mid-stage trial results announced by the pharmaceutical giant showed that patients taking orforglipron lost an average of ...

Drugmaker Eli Lilly said Thursday that an experimental pill form of popular GLP-1 medications helped people with type 2 ...

A new weight-loss pill taken daily could compete with injections like Ozempic, research suggests. Patients, who all were ...

Patients with obesity often report being shamed and stigmatized in medical settings. How can physicians address weight ...

In 2024, the FDA's Center for Drug Evaluation and Research (CDER) approved 50 new drugs. The CDER director, Patrizia ...

The once-daily pill, currently under investigation, is being studied for adults with type 2 diabetes who are not on any ...

In Australia, Ozempic is approved for the treatment of type 2 diabetes, while Wegovy is approved for weight management. Both ...

Cardio burns more calories per session, while weight training offers sustained metabolic benefits by building lean muscle.

Pfizer has made the decision to discontinue the clinical development program for danuglipron, an oral GLP-1 receptor agonist, being investigated for chronic weight management.

Drugmaker Eli Lilly said that in Phase 3 studies of over 550 adults, their oral GLP-1 pill, orforglipron, could reduce ...

Millions of dollars in a new state budget proposal could allow for the return of GLP-1 coverage for some state employees.